News

TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients’ Access to Life-Changing Medicines

Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan.   CAMBRIDGE, Mass., Feb. 12, 2025 /PRNewswire/…

10 months ago

Terrain Biosciences emerges from stealth to enable faster therapeutics and vaccine development with better RNA

- Founded by Professors Omar Abudayyeh, Jonathan Gootenberg, and Patrick Hsu leveraging novel AI models and technologies for designing, building,…

10 months ago

Dalan Animal Health Unlocks the Power of Innate Immunity for a New Era in Disease Prevention

ATHENS, Ga., Feb. 12, 2025 /PRNewswire/ -- Dalan Animal Health, a global leader in bioscience innovation, today announced a major breakthrough…

10 months ago

Clearsense Announces Strategic Rebrand and Relocation of Headquarters to Nashville

New market position highlights Clearsense as a leading healthcare data enablement platform, showcasing the transformative value of its solutions NASHVILLE,…

10 months ago

Nanomosaic Announced Release of Joint White Paper with BMS Investigating Nanoneedle Technology to Improve AAV Manufacturing Process and Product Quality

WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- Nanomosaic, a leader in multiplex, multi-omic marker analysis, today announced the publication of a scientific white paper detailing a study…

10 months ago

TE Connectivity to acquire Richards Manufacturing to expand position in fast-growing energy market

GALWAY, Ireland, Feb. 12, 2025 /PRNewswire/ -- TE Connectivity plc (NYSE: TEL), a world leader in connectors and sensors, has entered…

10 months ago

CorVista Health Announces Leadership Succession, Appointing Adrian Lam as President and CEO

Adrian Lam appointed President and CEO of CorVista HealthDon Crawford to retire following a distinguished 42-year career in MedTechTim Attebery…

10 months ago

NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update

Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million…

10 months ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control armsPhase 1/2 study (N=60) demonstrated favorable safety…

10 months ago

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with…

10 months ago